SynthesisJournal of neuro-oncology2025
Prevalence of human cytomegalovirus in glioblastoma multiforme: a systematic review and meta-analysis.
Synthesis in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman cytomegalovirus (HCMV) infection is implicated in glioblastoma pathogenesis through oncogenic and immunomodulatory mechanisms; however, prevalence estimates remain highly variable across studies, warranting systematic evaluation.
methodsWe systematically searched PubMed, Embase, LILACS, SciELO, and Cochrane for studies on HCMV detection in patients with glioblastoma. A single-arm meta-analysis estimated pooled prevalence with subgroup analyses by region, country, income level, antibody, and detection method. Random-effects models (95% CI) were applied, and heterogeneity quantified using I².
results19 studies comprising 988 glioblastoma patients were included, HCMV positivity was 68% (95% CI, 0.53 to 0.80; P < 0.0001; I² = 91.4%). Subgroup analyses revealed a significant prevalence in Europe and Central Asia (82%; 95% CI, 0.38 to 0.97; P < 0.0001; I² = 94.7%) and North America (78%; 95% CI, 0.23 to 0.98; P < 0.0001; I² = 94.3%), followed by Middle East/North Africa (72%; 95% CI, 0.45 to 0.89; P < 0.0001; I² = 87.4%), Latin America and Caribbean (65%; 95% CI, 0.25 to 0.91; P < 0.0001; I² = 85.5%), and East Asia and Pacific (51%; 95% CI, 0.16 to 0.86; P < 0.0001; I² = 94.6%). High-income and upper-middle-income countries have a predominance of 69% and 73% (95% CI, 0.40 to 0.88 and 0.52 to 0.87, P < 0.0001, I² = 95.2% and 83.5%) compared to lower-middle-income (53%; 95% CI, 0.25 to 0.79; P = 0.0012; I² = 90.4%). Technique methods influenced prevalence, with IHC showing 74% positivity versus 66% with PCR, and 65% with ELISA. Antibody analysis highlighted the significance of UL83 (95%) and IE-72 (87%) within studies.
conclusionThis meta-analysis revealed high HCMV detection in patients with glioblastoma, although results varied by region, income, technique, and antibody. Standardized protocols and large studies are needed to clarify HCMV’s role and implications for targeted therapies.
Indexed as
Identifiers
41460368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.